Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002453 (
amenorrhea
)
6,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Two euprolactinemic women with hypothalamic
amenorrhea
, previously unsuccessfully submitted to clomiphene citrate therapy, were treated with bromocriptine.
PRL
secretion was studied in basal conditions and under dynamic tests: TRH and chlorpromazine. Serum FSH, LH and 17-beta-estradiol were determined before and during the treatment. Both patients conceived, and one delivered a healthy baby at term. Bromocriptine appears to be an effective drug for treating women with hypothalamic
amenorrhea
, particularly those unresponsive to clomiphene.
...
PMID:Bromocriptine induced pregnancy in two cases of euprolactinemic hypothalamic amenorrhea. 11 66
The clinical courses of galactorrhea and menstrual disorders were studied in 18 women with galactorrhea induced by sulpiride (SLP) or metoclopramide (MCP) given for the treatment of gastrointestinal diseases. The response of
PRL
and TSH to 500 micrograms iv TRH and the response of LH and FSH to 100 micrograms LRH were assessed by retrospective analysis during treatment in nine patients (six, SLP; three, MCP) and shortly after the end of treatment in nine patients (seven, SLP; two, MCP). The average time from the initiation of treatment to the onset of galactorrhea was 27.2 +/- 4.7 (mean +/- SE) days in the 13 SLP-treated patients and 23.2 +/- 5.8 days in the 5 MCP-treated patients. Five of the SLP-treated patients experienced
amenorrhea
, four had oligomenorrhea, and one had dysfunctional bleeding. In the MCP-treated patients, oligomenorrhea and dysfunctional bleeding occurred in one each. The average length of time from the end of treatment to disappearance of galactorrhea was 50.0 +/- 7.3 days in the SLP-treated patients and 56.6 +/- 12.1 days in the MCP-treated patients. Cyclic uterine bleeding returned within 2 months after treatment was stopped. Elevated
PRL
levels with good response to TRH were observed in four of six patients during SLP treatment, and in two of three patients during MCP treatment. Basal
PRL
levels and response to TRH were normal in almost all patients after the drugs were withdrawn. Normal HL and FSH levels with exaggerated responses of LH to LRH were observed in most patients during treatment, whereas the response of LH to LRH was normal in about half of the patients after treatment. Our findings suggest that hyperprolactinemia in patients treated with SLP or MCP may be in part the cause of both galactorrhea and menstrual abnormalities, and that these symptoms can be reversed by stopping treatment, provided the patients have not taken the drugs for longer than a year.
...
PMID:Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. 12 11
An in vitro bioassay for plasma
PRL
-releasing factor-like activity has been developed. The method is a three-phase methanol extraction of plasma with extracts of 1.0 ml plasma adjusted to a final volume of 50 microliter. Single 50-microliter aliquots of extract were incubated in 1.0 ml Krebs-Ringer phosphate (KRP) buffer with one rat hemipituitary after a 1-h preincubation. Samples were obtained basally and 30 min after addition of the extract. During each set of incubations, a parallel series of hemipituitaries was incubated in KRP alone. The total nanograms of rat
PRL
released per mg pituitary tissue during the initial 30 min after preincubation was calculated for all studies. The mean quantity released in KRP alone was considered basal and was subtracted from values obtained during incubation with plasma extracts. The quantity remaining was considered
PRL
-releasing activity (PRA) of plasma, expressed as nanograms of rat
PRL
released per mg pituitary. The PRA in plasma from 13 patients with the
amenorrhea
-galactorrhea syndrome was 132 +/- 17 ng/mg pituitary (X +/- SE), which was significantly greater (P less than 0.001) than the PRA in plasma from eight matched controls [31 +/- 10 ng/mg pituitary (X +/- SE)]. The patients' individual
PRL
levels were elevated (range, 48-248 ng/ml), and when compared to the PRA in the samples, a highly significant (P less than 0.001) positive correlation evolved. These results indicate that a circulating
PRL
-releasing factor-like material present in normal plasma is higher in plasma from hyperprolactinemic patients in direct relationship to the
PRL
concentration. It is possible that this material is related to the pathogenesis of
PRL
-secreting pituitary disorders.
...
PMID:Plasma prolactin-releasing factor-like activity in the amenorrhea-galactorrhea syndrome. 12 15
Seven female patients with
amenorrhea
, galactorrhea, and hyperprolactinemia were examined before and after selective transsphenoidal removal of a
PRL
-secreting microadenoma. Before adenomectomy, metoclopramide (MCP; 10 mg orally) and TRH (200 micrograms iv) did not increase
PRL
blood levels in any of the seven patients. On the contrary, after oral administration of 10 mg MCP, a positive response was noted in a group of eight lactating women 3 days postpartum. After surgery, serum
PRL
level returned to normal in all patients. A positive
PRL
response to MCP and TRH was found in six of the seven patients 1 month after surgery. One patient, who had the lowest
PRL
level, failed to show a
PRL
increase after both stimuli. These findings indicate that hypothalamic pituitary function can be restored to normal after transsphenoidal removal of
PRL
-secreting pituitary tumors.
...
PMID:Serum prolactin response to thyrotropin-releasing hormone and metoclopramide in patients with prolactin-secreting tumors before and after transsphenoidal surgery. 12 21
A pituitary adenoma was removed from a young woman who had acromegaly with galactorrhea-
amenorrhea
. Postoperatively, the dysmorphic acromegalic syndrome and galactorrhea decreased but
amenorrhea
, elevated serum GH and
PRL
concentrations remained. After Bromocriptine administration (5 mg daily) GH and
PRL
levels became normal, vaginal bleeding ensued within 3 months and a twin pregnancy was induced. An immunocytochemical study of the pituitary adenoma revealed the presence of two well defined, distinct cell types, each secreting one hormone with large preponderance of GH cells.
...
PMID:[Twin pregnancy following bromocriptine in an acromegalic patient staying sterile after removal of a pituitary adenoma. Immunocytochemical study of the tumor (author's transl)]. 23 33
Neuroendocrine function in two women with galactorrhea-
amenorrhea
arising from abnormalities in the
PRL
reflex arc was compared to that of normal women. Basal gonadotropins were lower than normal, and one patient lacked episodic secretion of LH; however, the serum gonadotropin rise after iv LRH was in the normal range in both patients. Mean basal
PRL
levels were slightly elevated in one patient and were normal in the other, and the
PRL
levels after TRH, chlorpromazine, and levodopa testing were similar to those seen in normal women. Breast stimulation did not increase
PRL
levels in either patient.
PRL
levels fell with bromergocryptine therapy, galactorrhea ceased, and normal menses resumed. These studies indicate that chronic afferent impulses originating in the
PRL
reflex arc can result in galactorrhea and
amenorrhea
and that bromergocryptine therapy in such patients can restore normal menses.
...
PMID:Neurogenic galactorrhea-amenorrhea. 26 59
Bromocryptine treatment was administered to 15 patients with
amenorrhea
and galactorrhea (AG) and to 1 patient with
amenorrhea
. All of them had increased plasma
PRL
levels. Of these 16 patients, 4 had a normal sella turcica (ST; group STO), 4 had a slight enlargement (group ST+), and 7 had a clear enlargement of ST (ST++) but no evidence of suprasellar extension. Ovulation was restored in 15 patients by bromocryptine treatment only. In one patient, ovulation resumed only after human pituitary gonadotropin treatment in combination with bromocryptine. There was no correlation between basal prolactinemia,
PRL
stimulability or suppressibility, the size of ST, or the efficiency of bromocryptine treatment. Every patient with normal LH response to either LRH or clomiphene or both resumed ovulation. Ovulation resumed in 3 patients among the 4 with abnormal LH response to either LRH or clomiphene or both. Among the 14 who desired pregnancy, 13 became pregnant. To date, 12 patients (ST++, 5; ST+, 3; STO, 4) have delivered normal babies. The courses of pregnancy were normal. During pregnancy, no change of ST was noted on lateral and frontal skull x-ray performed in every patient at trimonthly intervals. There was no change in the sellar index in 10 patients after pregnancy, as compared to the pretreatment status. In the presence of a pituitary adenoma or in patients with hyperprolactinemia and
amenorrhea
and galactorrhea, bromocryptine treatment may cure sterility without pituitary complication during pregnancy.
...
PMID:Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. 40 Jul 17
In eleven normal women dopamine infusion (5 microgram/Kg/min) significantly lowered plasma prolactin levels but failed to suppress the
PRL
response to sulpiride (10 or 100 mg i.v.), while the same dose of dopamine was effective in abolishing the
PRL
response to TRH (200 microgram i.v.). In four hyperprolactinemic women showing an impaired
PRL
response to sulpiride, dopamine infusion was effective both in lowering
PRL
circulating levels and in restoring an evident response to sulpiride. This finding suggests an impairment of endogenous dopamine activity in hyperprolactinemic
amenorrhea
.
...
PMID:Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects. 41 Aug 26
The acute effect of pyridoxine (B6) on serum GH and
PRL
levels and its chronic effects on galactorrhea in nine subjects (group I, n=4, idiopathic galactorrhea with normal
PRL
levels and normal menses; Group II, n=5, galactorrhea-
amenorrhea
with increased
PRL
levels) have been studied. Pyridoxine did not acutely alter GH or
PRL
levels. There was no decrease in galactorrhea, no resumption of menses and no decrease in
PRL
following tow months of B6 therapy. In contrast, bromocriptine was effective in suppressing galactorrhea and restoring normal menses in group II subjects and remains the therapy of choice for this purpose.
...
PMID:Ineffectiveness of pyridoxine (B6) to alter secretion of growth hormone and prolactin and absence of therapeutic effects on galactorrhea-amenorrhea syndromes. 55 90
A young, adult, white female with long-standing
amenorrhea
-galactorrhea syndrome and known pituitary enlargement since 1969 is presented. Further evaluation revealed
PRL
levels elevated in the microadenoma range and an empty sella. The presence of a pituitary adenoma, however, could not be confirmed by our studies. The question now arises--in a young woman desirous of pregnancy, should an induction of ovulation be attempted in view of the elevated serum
PRL
and an empty sella?
...
PMID:Primary empty sella syndrome with elevated serum prolactin. 56 54
1
2
3
4
5
6
7
8
9
10
Next >>